Zymeworks Inc
NASDAQ:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NASDAQ:ZYME
Watchlist
Price: 14.08 USD -0.85% Market Closed
Market Cap: 973.8m USD
Have any thoughts about
Zymeworks Inc?
Write Note

Zymeworks Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zymeworks Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Zymeworks Inc
NASDAQ:ZYME
Pre-Tax Income
-$118m
CAGR 3-Years
17%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Zymeworks Inc
Glance View

Market Cap
987.8m USD
Industry
Biotechnology

Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

ZYME Intrinsic Value
18.33 USD
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Zymeworks Inc's Pre-Tax Income?
Pre-Tax Income
-118m USD

Based on the financial report for Sep 30, 2024, Zymeworks Inc's Pre-Tax Income amounts to -118m USD.

What is Zymeworks Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-13%

The average annual Pre-Tax Income growth rates for Zymeworks Inc have been 17% over the past three years , -13% over the past five years .

Back to Top